Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.70, read 2026-11-01
Ethical does not pass the values gate
Price366.57 USD
Fair value408.10
Ethical score10.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-04Read Markup353.92+3.6% to today ✓Accumulation gives way to Markup after an 11% rise in 2 weeks
2026-10-18Read Accumulation317.95+15.3% to today ✓Markup gives way to Accumulation
2026-10-11Read Markup309.57+18.4% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-02Read Distribution309.57+18.4% to today Accumulation gives way to Distribution after an 8% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Labcorp holds its Markup at $366.57. The statistical read favours the sellers, held for 2 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 2 days
Price at the screen
$366.57
Valuation
29.62 trailing · 18.33 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.48%
Below 33%
Interest-bearing debt is 35.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.84%
Below 33%
Cash held in interest-bearing accounts and securities is 0.8% of assets, under the one-third limit.
Pass
Receivables
14.33%
Below 49%
Money owed to the company is 14.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Labcorp's business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LH's ethical verdict changes
Today LH does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly an 11% discount to our $408.10 fair value, narrow competitive moat, 6.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 10.2% discount to the base estimate.
Where our models see it going: fair-value estimate $408.10, with a range of $325.27 to $542.12, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 7%-growth business trading at just 18.3x forward earnings, with a narrow competitive moat. That is an 11% discount to our $408.10 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 16 analysts rate it Buy with a $382.50 average target, about 4% above the screened price.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup · changed$353.92+11.3%Entry 17
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310.
2026-10-28Accumulation$317.95+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$317.95+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$317.95+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$317.95+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$317.95+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$317.95+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$317.95+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$317.95+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
